The oversubscribed round will support final assay development and manufacturing readiness for an early access program launch.
The study included 3,014 patients evaluated based on high-risk screening, symptomatic presentation, or identification of a mass on imaging.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results